Denosumab @ ASH 2019
Daten zum Progressionsfreien Überleben mit Denosumab versus Zoledronsäure bei Patienten mit Multiplen Myelom
Daten zum Progressionsfreien Überleben mit Denosumab versus Zoledronsäure bei Patienten mit Multiplen Myelom
You are now leaving oncologyhorizons.at
Amgen does not endorse or accept liability for sites controlled by third parties
You are now leaving oncologyhorizons.at
Amgen does not endorse or accept liability for sites controlled by third parties
You are now leaving oncologyhorizons.at
Amgen does not endorse or accept liability for sites controlled by third parties